title: [Carrier-mediated Transport of Cationic Drugs across the Blood-Tissue Barrier].
abstract: Studies of neurological dysfunction have revealed the neuroprotective effect of several cationic drugs, suggesting their usefulness in the treatment of neurological diseases. In the brain and retina, blood-tissue barriers such as blood-brain barrier (BBB) and blood-retinal barrier (BRB) are formed to restrict nonspecific solute transport between the circulating blood and neural tissues. Therefore study of cationic drug transport at these barriers is essential to achieve systemic delivery of neuroprotective agents into the neural tissues. In the retina, severe diseases such as diabetic retinopathy and macular degeneration can cause neurological dysfunction that dramatically affects patients' QOL. The BRB is formed by retinal capillary endothelial cells (inner BRB) and retinal pigment epithelial cells (outer BRB). Blood-to-retina transport of cationic drugs was investigated at the inner BRB, which is known to nourish two thirds of the retina. Blood-to-retinal transport of verapamil suggested that the barrier function of the BRB differs from that of the BBB. Moreover, carrier-mediated transport of verapamil and pyrilamine revealed the involvement of novel organic cation transporters at the inner BRB. The identified transport systems for cationic drugs are sensitive to several cationic neuroprotective and anti-angiogenic agents such as clonidine and propranolol, and the involvement of novel transporters was also suggested in their blood-to-retina transport across the inner BRB.
authors.affiliation: Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kubo
mesh_terms: D020533:Angiogenesis Inhibitors / Q000493:pharmacokinetics; D001692:Biological Transport; D001812:Blood-Brain Barrier / Q000378:metabolism*; D001813:Blood-Retinal Barrier / Q000378:metabolism*; D027682:Cation Transport Proteins / Q000378:metabolism / Q000502:physiology; D003000:Clonidine / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000493:pharmacokinetics*; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy* / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000493:pharmacokinetics*; D011433:Propranolol / Q000493:pharmacokinetics; D011738:Pyrilamine / Q000493:pharmacokinetics; D014700:Verapamil / Q000493:pharmacokinetics
chemical_list: D020533:Angiogenesis Inhibitors; D027682:Cation Transport Proteins; D004337:Drug Carriers; D018696:Neuroprotective Agents; D011433:Propranolol; D014700:Verapamil; D011738:Pyrilamine; D003000:Clonidine